APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

APL-101 has a biologically credible lead setting because MET exon 14 skipping NSCLC is a validated oncogenic driver, and ORR by independent central review is a reasonably clean phase 2 efficacy endpoint for a targeted therapy. However, this study is not a focused single-cohort program. It is a broad basket spanning MET exon 14, MET amplification, MET fusion, HGF/MET overexpression, CNS tumors, and EGFR-resistant combination use, so the underlying response probability is likely very uneven across cohorts. That design increases the chance of mixed data rather than a clearly positive overall readout. The trial also appears operationally strained: it is still recruiting even though the estimated primary completion date has just passed, which can signal slow accrual, fragmented cohort sizes, or immature disclosure. In heavily pretreated advanced tumors, even mechanistically sound drugs often produce patchy phase 2 activity. Netting strong target biology against basket heterogeneity and execution risk, I put the chance of a clearly positive market-resolving result below 50%.

APL-101 (vebreltinib/bozitinib) is a selective MET inhibitor targeting MET exon 14 skipping mutations and MET dysregulation across multiple tumor types. The trial is a Phase 2 basket study sponsored by Apollomics, a small-cap biotech. Several factors temper optimism: (1) The study spans a very broad set of indications—NSCLC, renal, gastric, GBM, thyroid, pancreatic, colon—making a cleanly 'positive' readout across all cohorts unlikely. (2) While MET exon 14 skip NSCLC is a validated target (capmatinib, tepotinib approved), APL-101 faces a high bar in a competitive landscape with established agents. (3) The trial is still listed as 'Recruiting' despite an estimated primary completion date that has passed (March 30, 2026), suggesting enrollment challenges or timeline slippage, which often correlates with smaller-than-planned sample sizes and underpowered results. (4) Apollomics is a micro-cap company with limited resources, raising execution risk. (5) ORR by BIRC per RECIST is a reasonable endpoint, but basket trials frequently show mixed results across cohorts. The MET exon 14 NSCLC cohort has the best chance of positivity based on class-level evidence, but overall trial success probability is moderate at best. I estimate ~45% intrinsic probability of a positive readout.

This Phase 2 trial evaluates APL-101 (a MET inhibitor) in NSCLC and other solid tumors with MET alterations including exon 14 skipping mutations, amplifications, and fusions. MET exon 14 skipping is a validated oncogenic driver with established therapeutic vulnerability. The primary endpoint is ORR per IRC (independent review), which adds rigor. The trial includes both monotherapy and combination arms (with EGFR inhibitors). Prior MET inhibitor data in this space has shown meaningful response rates. The trial has reached primary completion (daysToPrimaryCompletion = -3). Phase 2 studies with clear molecular targeting and ORR endpoints in selected populations typically have reasonable success rates. However, the broad tumor type inclusion and the complexity of MET dysregulation across indications introduces heterogeneity risk. Overall, the targeted mechanism and defined patient selection support a modest positive bias.

The trial is a Phase 2 basket study targeting heterogeneous MET alterations across multiple solid tumors, which dilutes signal and complicates statistical power for any single cohort. The primary completion date has passed with no data readout reported, and the status remains 'Recruiting,' suggesting enrollment or operational delays. The primary endpoint (ORR per IRC) is standard, but the broad, multi-cohort design increases the risk of failing to meet significance thresholds in key populations. While prior data for c-MET inhibitors exists, Apollomics is a small biotech, and the add-on therapy cohort introduces further complexity. Overall, the probability of a clear, positive result across the study's ambitious scope appears below 50%.

This Phase 2 basket trial evaluates APL-101, a MET inhibitor, across multiple cohorts: NSCLC with MET exon 14 skipping or amplification, other MET-altered solid tumors, CNS tumors, and EGFR-resistant NSCLC combo. Biomarker-enriched population (e.g., METex14 NSCLC) mirrors approved agents like capmatinib/tepotinib with ORR 40-70%, supporting efficacy potential. Primary endpoint ORR by blinded IRC (RECIST/RANO) is high-quality, minimizing bias. However, diverse indications (gastric, renal, thyroid, etc.) and rarer alterations (MET fusion, HGF overexpression) dilute focus and precedent. Trial operational risks evident: initiated 2017, primary completion delayed to 2026, still recruiting despite -3 days to date, suggesting enrollment/execution challenges. No interim/prior data provided; assumes Phase 1 safety but unproven superiority. Positivity likely requires NSCLCex14 ORR >30-40%; basket complexity tempers odds. Sponsor disclosure probable post-topline.

The trial focuses on MET Exon 14 skipping mutations and MET amplification. While early-phase data for similar c-Met inhibitors in this specific mutation is promising, the inclusion of multiple solid tumor types creates significant heterogeneity. The primary endpoint, ORR, is a binary outcome that can be clinically difficult to predict. The sponsor, Apollomics, is a smaller biotech, adding operational risk. The drug, Vebreltynib (APL-101), has shown efficacy signals, but the complexity of a multi-arm, multi-indication study increases the risk of a 'failed' neutral outcome. The probability of a clearly positive readout (statistically significant improvement) is less than 50%.

APL-101 is a c-Met inhibitor tested across diverse tumor types with MET alterations. The trial design is broad—spanning NSCLC Exon 14 skip, MET amplification, fusions, CNS tumors, and combination with EGFR inhibitors—creating heterogeneity that dilutes signal. Primary endpoint ORR by BIRC is standard but the basket design means powering is spread thin across subgroups. The sponsor Apollomics is a smaller biotech with limited Phase 2 track record. c-Met inhibitors like capmatinib and tepotinib have already shown efficacy in MET Exon 14 NSCLC, setting a competitive bar. The trial completed primary completion 3 days ago with no data disclosure yet, suggesting potential delay or data cleaning issues. Multi-indication basket trials historically have mixed success; without clear prior Phase 1b data cited, the probability of meeting positive ORR thresholds across key cohorts is modest. Disclosure risk is elevated given completion date passed.

The SPARTA trial evaluates vebreltinib (APL-101) in MET-dysregulated solid tumors, primarily MET exon 14 skipping NSCLC. Vebreltinib is a highly selective c-MET inhibitor, a proven mechanism with approved analogues like capmatinib. Prior interim data for APL-101 demonstrated an objective response rate (ORR) of 67% in MET exon 14 skipping NSCLC and 43% in MET fusion solid tumors, which aligns well with efficacy expectations for this class and indicates strong biological activity. Furthermore, vebreltinib has already received conditional approval in China, heavily de-risking the clinical profile. Although Apollomics faced severe financial distress in 2025—even announcing a potential wind-down—the company reversed this decision. Crucially, on March 30, 2026, the CEO injected a $2M 0% interest bridge loan to sustain operations ahead of a planned $10M equity raise. This insider financial commitment, occurring precisely at the trial's estimated primary completion date, signals high management confidence in the upcoming trial results. The biological risk is minimal given the target validation and prior interim readouts, leaving the primary risk as operational or funding-related delays. With funding temporarily secured, the likelihood of a positive result is very high.

The APL-101 study targets NSCLC patients with c-Met EXON 14 skip mutations and c-Met dysregulation, focusing on a specific genetic subset with high unmet medical need. The trial's design and primary endpoint (ORR per IRC) are appropriate for assessing efficacy in this population. Given the targeted approach and the mechanism of action of APL-101, there is a reasonable basis for expecting a positive outcome, although the small sample size and Phase 2 status introduce uncertainty.